GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
Executive Summary
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
You may also be interested in...
Generic Coreg To Launch Immediately Following FDA Approval
The first generic versions of GlaxoSmithKline's blockbuster heart failure medication Coreg (carvedilol) will launch immediately following FDA's Sept. 5 approval of several ANDAs for the beta blocker
Reliant Will Add Antara, Omacor To Cardiovascular Product Line In 2005
Reliant will launch two recently-approved cardiovascular products, Antara and Omacor, in 2005
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.